Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
visugromab (CTL-002) in advanced solid tumors
NCT04725474Phase 2Active, not recruiting
- Sponsor
- CatalYm
- Start
- Dec 2020
- Primary completion
- Apr 2028
- Countries
- 3
01
Overview
A Phase 2 trial of visugromab in solid tumor, bladder cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), melanoma, sponsored by CatalYm. Started Dec 2020; status: active, not recruiting.
02
Drugs
visugromab
03
Conditions
solid tumorbladder cancerhepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT04725474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725474.